


STUDY OF MONOCYTE PRO-COAGULANT  
ACTIVITY IN ANTIPHOSPHOLIPID SYNDROME

Thesis

Submitted for the partial fulfilment of   
master degree in Biochemistry

By

**Wael Mohammad El-Sayed El-Ayat**

M.B.B.Ch.

612.115  
W. M.

Supervised by

**Prof. Dr. Salah Eldin Zaki Eid**

*Professor of Biochemistry,  
Faculty of Medicine,  
Ain Shams University*

**Dr. Noura Mohammad El-Kholy**

*Assist. Prof. Of Biochemistry,  
Faculty of Medicine,  
Ain Shams University*

*Faculty of Medicine,  
Ain Shams University*



1996





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ

الْكَبِيرُ ﴾

صدق الله العظيم

سورة البقرة الآية (٣٢)



**TO MY FAMILY**  
TO MY FAMILY



## **ACKNOWLEDGEMENT**

I wish to express my cordial thanks and gratitude to **PROF. DR. SALAH ELDIN ZAKI EID**, Professor of Biochemistry, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under his supervision, for his encouragement, continuous support, patience, fruitful comments and constructive supervision throughout this work. His sincere efforts to provide all the facilities to carry out this work are beyond acknowledgement.

I am deeply indebted and grateful to **Dr. Noura Mohammad El-Kholy**, Assistant Professor of Biochemistry, Faculty of medicine, Ain Shams University, for suggesting the subject of this thesis, for her generous guidance throughout the practical part of this work, and for her great help in writing and revising the manuscript.

Deepest thanks are owed To **Dr. Salah Taha Fayed**, Lecturer of Obstetric and Gynaecology, Faculty of Medicine, Ain Shams University for selecting the subjects of this thesis.

Finally, I wish to express my thanks to all the members of the Biochemistry Department, Ain Shams Faculty of Medicine for their kind help and cooperation.



# ***CONTENTS***

	<b><i>Page</i></b>
<b>Introduction and aim of the work</b>	<b>1</b>
<b>Review of literature</b>	<b>3</b>
<i>Antiphospholipid syndrome</i>	<b>3</b>
<i>Antiphospholipid antibodies</i>	<b>24</b>
<i>Monocytes</i>	<b>39</b>
<i>Monocyte Pro-coagulant activity</i>	<b>41</b>
<b>Subject and methods</b>	<b>57</b>
<b>Results</b>	<b>76</b>
<b>Discussion</b>	<b>92</b>
<b>Summary and conclusion</b>	<b>98</b>
<b>References</b>	<b>100</b>
<b>Arabic Summary</b>	



## **ABBREVIATIONS**

PCA	Procoagulant activity
TF	Tissue factor
LPS	Lipopolysaccharide
APS	Antiphospholipid syndrome
SLE	Systemic lupus erythematosus
APAs	Antiphospholipid antibodies
LA	Lupus Anticoagulant
ACA	Anticardiolipin antibody
PGI <sub>2</sub>	Prostacyclin
β <sub>2</sub> -GPI	Beta <sub>2</sub> Glycoprotein I
Ig	Immunoglobulin
IL-3	Interleukin-3
TTP	Thrombocytopenic Purpura
DIC	Disseminated Intravascular Coagulopathy
PT	Prothrombin Time
APTT	Activated Partial Thromboplastin Time
VDRL	Venerial Disease Research Laboratory Test
ELISA	Enzyme Linked Immunosorbant assay
ssDNA	Single Stranded DNA
dsDNA	Double Stranded DNA
IP <sub>3</sub>	Inositol Triphosphate
KCT	Kaolin Cloting Time
dRVVT	Dilute Russel's Viper Venom Time
TNF	Tumor necrosis factor
M-CSF	Macrophages Colony stimulating factor
IFN	Interferon
LAL	Limulus amebocyte Lysate
KDO-3	2 Keto-3 deoxy octonic acid
GLCN	Glycosaminyl Residue
LBP	Lipopolysaccharid Binding Protein
GPI	Glycosyl Phosphatidyl Inositol
sCD 14	Soluble CD 14

rs CD14	Recombinant Soluble CD 14
HDL	High Density Lipoprotein
APOA	Apolipoprotein A
EC	Endothelial Cells
Le (x)	Lewis (x)
Sle (x)	Sialyl-Le (x)
MW	Molecular Weight
CDCA	Chenodeoxy Cholic Acid
PKC	Protein Kinase C
mRNA	Messenger RNA
TFPI	Tissue Factor Pathway Inhibitor
EPI	Extrinsic Pathway Inhibitor
ACD	Acid Citrate Dextrose
PRP	Platelet Rich Plasma
OPD	Ortho-phenylendiamine
PL	Phospholipid
UV	Ultra-Violet
SDS PAGE	Sodium Dodecyl Sulfate Poly acrylamide Electrophoresis
TEMED	Tetramethyl Ethylendiamine
PBS	Phosphate Buffered Saline
HBSS	Hanks Balanced Salt Solution
HEPES	N-[2-Hydroxy Ethyl] Piperazine -N <sup>3</sup> -[2- ethane sulfonic acid].

## **LIST OF TABLE**

	<b>PAGE</b>
<b>TABLE (1)</b> Major features of antiphospholipid syndrome.	4
<b>TABLE (2)</b> Disease states which should be excluded in patients with unexplained venous thrombosis.	20
<b>TABLE (3)</b> Potential causes of bleeding in patients with lupus anticoagulant .	21
<b>TABLE (4)</b> Classification of lupus anticoagulants.	25
<b>TABLE (5)</b> Common terms for antiphospholipid antibodies.	25
<b>TABLE (6)</b> Results of determination of antiphospholipid antibody in patients with recurrent fetal loss	79
<b>TABLE (7)</b> Effect of APA+ve plasma on monocyte PCA determined by a one-stage clotting assay with normal plasma.	80
<b>TABLE (8)</b> Effect of APA+ve plasma on monocyte PCA determined by a one-stage clotting assay with factor VII deficient plasma.	81
<b>TABLE (9)</b> Effect of APA+ve plasma on monocyte PCA determined by a one-stage clotting assay with factor IX deficient plasma.	82
<b>TABLE (10)</b> Comparison of the effects of APA+ve and control APA-ve plasma on the LPS stimulated monocyte procoagulant activity .	83
<b>TABLE (11)</b> Comparison of the effect of purified antiphospholipid IgG and control IgG on the LPS-stimulated monocyte PCA.	84

